ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual results, with full-year revenue reaching RMB1.06 billion, a 35.1% year-on-year increase. Net profit surged 143.7% to RMB244 million. The strong performance was attributed to higher sales of core products, accelerated expansion of international operations, and improved operational efficiency. Additionally, ZYLOXTB announced it exercised an option to acquire 11% of Optimed Holding and plans to acquire the remaining 40% in the first half of 2028, taking full ownership. The total estimated cost is up to €41.17 million (approximately RMB326 million). Optimed is a German medical technology company focused on the research, development, production, and global sales of minimally invasive vascular and urological interventional medical devices.